Newsroom

LONDON--(BUSINESS WIRE)--Janus Henderson Group plc (NYSE: JHG; “JHG," "Janus Henderson,” or the “Company”) today confirmed that the Special Committee of the Janus Henderson Board of Directors (the “Special Committee”) received an unsolicited, non-binding proposal. On December 22, 2025, Janus Henderson announced that it had entered into a definitive merger agreement (the “merger agreement”) providing for the acquisition of Janus Henderson by Trian Fund Management, L.P. and its affiliated funds (...

SASKATOON, Saskatchewan--(BUSINESS WIRE)--Nutrien Ltd. (TSX and NYSE: NTR) announced today that the Toronto Stock Exchange (TSX) has accepted Nutrien's notice to commence a normal course issuer bid (NCIB) to purchase outstanding common shares representing up to five percent of its issued and outstanding common shares. Under the NCIB, purchases of common shares may be made through the facilities of the TSX, the New York Stock Exchange and/or alternative trading systems in Canada and the U.S., or...

PHOENIX--(BUSINESS WIRE)--Cable One, Inc. (NYSE: CABO) (the “Company” or “Cable One”) today announced that it has granted equity awards to James A. Holanda as a material inducement to Mr. Holanda’s acceptance of employment with the Company as its Chief Executive Officer. The equity awards are consistent with the previously disclosed terms of Mr. Holanda’s offer letter and were approved by the Board of Directors (the “Board”) and the Compensation and Talent Management Committee of the Board in r...

OLDWICK, N.J.--(BUSINESS WIRE)--AM Best has assigned a Long-Term Issue Credit Rating of “bbb+” (Good) to the newly issued $1 billion, 5.85% subordinated debentures, due March 15, 2056, issued by MetLife, Inc. (MetLife) (headquartered in New York, NY) [NYSE: MET]. The outlook assigned to this Credit Rating (rating) is stable. All other ratings of MetLife and its subsidiaries remain unchanged. The proceeds from this debt issuance are expected to be used to cover general business purposes. MetLife...

LOS ÁNGELES--(BUSINESS WIRE)--Kairos Pharma, Ltd. (NYSE American: KAPA), empresa biofarmacéutica en etapa clínica enfocada en terapias oncológicas innovadoras, anunció hoy la firma de un acuerdo preliminar para la adquisición estratégica de activos de Celyn Therapeutics, Inc., empresa biotecnológica privada respaldada por OrbiMed y Torrey Pines Investment. Conforme a los términos propuestos, Kairos Pharma adquirirá los derechos mundiales sobre dos activos oncológicos altamente diferenciados en...

LOS ANGELES--(BUSINESS WIRE)--A Kairos Pharma, Ltd. (NYSE American: KAPA), empresa biofarmacêutica em fase clínica focada em tratamentos inovadores para o câncer, anunciou hoje a assinatura de um termo de compromisso com a Celyn Therapeutics, Inc., empresa de biotecnologia de capital fechado com o suporte da OrbiMed e da Torrey Pines Investment, para a aquisição estratégica de ativos. Segundo os termos propostos no acordo, a Kairos Pharma adquirirá os direitos mundiais de dois ativos oncológico...

MONTCLAIR, New Jersey--(BUSINESS WIRE)--Sitetracker, der weltweit führende Anbieter von Komplettlösungen für das Asset Lifecycle Management kritischer Infrastrukturen, gab heute starke Jahresendergebnisse für 2025 bekannt, die durch kontinuierliches Kundenwachstum, die Expansion in neue Infrastrukturmärkte und wichtige Produktinnovationen in den Bereichen Betrieb, Wartung und Finanzmanagement gekennzeichnet sind. Da Infrastrukturbesitzer und -betreiber einem wachsenden Druck ausgesetzt sind, oh...

LOS ANGELES--(BUSINESS WIRE)--Kairos Pharma, Ltd. (NYSE American: KAPA), ein biopharmazeutisches Unternehmen im klinischen Stadium, das sich auf innovative Krebstherapeutika konzentriert, gibt heute die Unterzeichnung eines Term Sheets für eine strategische Akquisition von Vermögenswerten mit Celyn Therapeutics, Inc. bekannt, einem privaten Biotechnologieunternehmen, das von OrbiMed und Torrey Pines Investment unterstützt wird. Gemäß den vorgeschlagenen Vertragsbedingungen erwirbt Kairos Pharma...

LOS ANGELES--(BUSINESS WIRE)--Kairos Pharma, Ltd. (NYSE American : KAPA), une société biopharmaceutique de phase clinique axée sur les thérapies innovantes contre le cancer, annonce aujourd'hui la signature d'une feuille de modalités visant l'acquisition d'actifs stratégiques avec Celyn Therapeutics, Inc., une biotech privée soutenue par OrbiMed et Torrey Pines Investment. Selon les termes proposés de l'accord, Kairos Pharma acquerra des droits mondiaux sur deux actifs en oncologie hautement di...

NEW YORK--(BUSINESS WIRE)--Klarna Group plc (NYSE: KLAR) today published its full year 2025 results for the period ended December 31, 2025. The results and related materials can be found on Klarna's Investor Relations website at https://investors.klarna.com/ Full Year 2025 Summary GMV of $127.9 billion (+22% YoY) Total Revenue of $3.5 billion (+25% YoY) Adjusted Operating Profit of $65 million (adjusted operating margin of 1.9%) Basic / Diluted EPS of $(0.79) for FY’25 - Q4 EPS $(0.12) 118 mill...